Matthias Eder
Impact in
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
- Hematology 70
- Acute Myeloid Leukemia Research 41
- Hematopoietic Stem Cell Transplantation 35
- Chronic Myeloid Leukemia Treatments 21
-
- Radiopharmaceutical Chemistry and Applications 52
- Co-authors
- Uwe Haberkorn (44 shared papers)Michaela Scherr (49 shared papers)Klaus Kopka (35 shared papers)Ali Afshar‐Oromieh (19 shared papers)Walter Mier (20 shared papers)Martin Schäfer (22 shared papers)Arnold Ganser (72 shared papers)Frederik L. Giesel (16 shared papers)
- Journals
- Blood (26 papers)European Journal of Nuclear Medicine and Molecular Imaging (15 papers)Journal of Nuclear Medicine (10 papers)Bone Marrow Transplantation (8 papers)Annals of Hematology (7 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Matthias Eder
188 papers receiving 13.0k citations
Matthias Eder's Hit Papers
Peers
Comparison fields: 5 of 145
- Radiology, Nuclear Medicine and Imaging 5.9k
- Pulmonary and Respiratory Medicine 6.1k
- Hematology 1.6k
- Oncology 3.3k
- Cancer Research 1.4k
Countries citing papers authored by Matthias Eder
This map shows the geographic impact of Matthias Eder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Eder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Eder more than expected).
Fields of papers citing papers by Matthias Eder
This network shows the impact of papers produced by Matthias Eder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Eder. The network helps show where Matthias Eder may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthias Eder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 199 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia Hit paper breakdown → | 2006 | 964 |
| 2 | The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Hit paper breakdown → | 2014 | 785 |
| 3 | Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer Hit paper breakdown → | 2013 | 712 |
| 4 | 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging Hit paper breakdown → | 2012 | 688 |
| 5 | Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer Hit paper breakdown → | 2015 | 464 |
| 6 | PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 Hit paper breakdown → | 2016 | 463 |
| 7 | 1994 | 434 | |
| 8 | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Hit paper breakdown → | 2017 | 400 |
| 9 | The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions Hit paper breakdown → | 2015 | 332 |
| 10 | Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer Hit paper breakdown → | 2014 | 317 |
| 11 | 2007 | 282 | |
| 12 | 2013 | 257 | |
| 13 | 2012 | 254 | |
| 14 | 2003 | 200 | |
| 15 | 1990 | 196 | |
| 16 | 2016 | 195 | |
| 17 | 1990 | 192 | |
| 18 | 2009 | 190 | |
| 19 | [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer Hit paper breakdown → | 2022 | 171 |
| 20 | 2016 | 169 |
About Matthias Eder
Matthias Eder is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, having authored 199 papers that have together received 13.2k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (52 papers), Prostate Cancer Treatment and Research (47 papers), Acute Myeloid Leukemia Research (41 papers), Hematopoietic Stem Cell Transplantation (35 papers), RNA Interference and Gene Delivery (24 papers), Chronic Myeloid Leukemia Treatments (21 papers), Acute Lymphoblastic Leukemia research (19 papers) and Peptidase Inhibition and Analysis (18 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (5.9k citations), Pulmonary and Respiratory Medicine (6.1k citations), Hematology (1.6k citations), Oncology (3.3k citations) and Cancer Research (1.4k citations). Matthias Eder has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Uwe Haberkorn, Michaela Scherr, Klaus Kopka, Ali Afshar‐Oromieh, Walter Mier, Martin Schäfer, Arnold Ganser, Frederik L. Giesel, Ulrike Bauder‐Wüst and Michael Eisenhut. Their work appears in journals such as Blood, European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, Bone Marrow Transplantation and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.